Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,677.98
(
-0.57%
)
US TECH 100
24,028.80
(
-0.43%
)
Dow Jones
46,557.88
(
-0.93%
)
Brent Oil
105.38
(
4.69%
)
Bitcoin
71,249.01
(
-3.64%
)
News Focus
News Focus
Post# of 818394
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

learningcurve2020

Send PM Follow Ignore
Followers 48
Posts 23481
Boards Moderated 0
Alias Born 09/16/2012

learningcurve2020

Re: tunnelvisionofplenty post# 736897

Wednesday, 12/11/2024 10:33:49 PM

Wednesday, December 11, 2024 10:33:49 PM

Post# of 818394
I doubt DCVAX falls under "Highly personalized".  That's likely reserved for therapies targeted to a patients genetic makeup. DNA, Crispr for rare disease.  


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News
InvestorsHub NewsWire

Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM

ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM

ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM

Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM

Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM

Start posting your company's news
Only $200 per official company press release!